# OnCo record endometrial (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/endometrial/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "endometrial" ;
  schema:name "Endometrial cancer"@en ;
  schema:alternateName "UCEC"@en, "TCGA-UCEC"@en, "uterine corpus endometrial carcinoma (TCGA and CPTAC UCEC cohorts)"@en ;
  schema:description "The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."@en ;
  schema:url <https://onco.cc/cancers/endometrial/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q944777> ;
  schema:citation <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  onco:tag "gyn", "spike" ;
  onco:related <https://onco.cc/pairings/chemo-io-first-line-endometrial/>, <https://onco.cc/pairings/lenvatinib-plus-pembrolizumab/>, <https://onco.cc/pairings/io-plus-vegf/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/fertility-sparing-endometrial/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/robotic-surgery/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/megestrol/> ;
  onco:companies <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/gsk/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/eisai/>, <https://onco.cc/companies/karyopharm/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/nrg-oncology/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/endometrial-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/nct07044336/>, <https://onco.cc/trials/nct06340568/>, <https://onco.cc/trials/nct06584032/>, <https://onco.cc/trials/nct06989112/>, <https://onco.cc/trials/nct06486441/>, <https://onco.cc/trials/nct07166094/>, <https://onco.cc/trials/nct06952504/>, <https://onco.cc/trials/nct05797831/>, <https://onco.cc/trials/nct06132958/>, <https://onco.cc/trials/nct06746116/>, <https://onco.cc/trials/nct07022483/>, <https://onco.cc/trials/nct07286331/>, <https://onco.cc/trials/nct05862272/>, <https://onco.cc/trials/nct05173987/>, <https://onco.cc/trials/nct04634877/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-capp2-aspirin-lynch-lancet-2020/>, <https://onco.cc/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/> ;
  onco:journals <https://onco.cc/journals/international-journal-of-gynecological-cancer/>, <https://onco.cc/journals/journal-of-gynecologic-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/puxitatug-samrotecan/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/hs-20089/>, <https://onco.cc/drugs/avzo-021/>, <https://onco.cc/drugs/serabelisib/>, <https://onco.cc/drugs/sapanisertib/>, <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/lorigerlimab/>, <https://onco.cc/drugs/eik1005/>, <https://onco.cc/drugs/vudalimab/>, <https://onco.cc/drugs/np137/>, <https://onco.cc/drugs/rinatabart-sesutecan/>, <https://onco.cc/trials/rainfol-01/>, <https://onco.cc/drugs/luveltamab-tazevibulin/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/>, <https://onco.cc/ideas/idea-her2-adc-serous-endometrial/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/msi/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/trials/fires-sentor/>, <https://onco.cc/technologies/fertility-sparing-endometrial/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/trials/portec-3/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/trials/ruby/>, <https://onco.cc/trials/nrg-gy018-keynote-868/>, <https://onco.cc/trials/duo-e/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/pairings/chemo-io-first-line-endometrial/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-775/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/msi/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/targets/her2/>, <https://onco.cc/trials/destiny-pantumor02/> .